713P Pembrolizumab (Pembro) vs placebo (Pbo) as second-line treatment for sorafenib-treated advanced hepatocellular carcinoma (aHCC): 4.5-year follow-up from KEYNOTE-240
- Resource Type
- Source
- Annals of Oncology. 33:S868-S869
- Subject
Oncology Hematology - Language
- ISSN
- 0923-7534